Neoadjuvant chemotherapy in geriatric head and neck cancers

被引：4

作者：

Patil, Vijay M. ^{[1
]}

Noronha, Vanita ^{[1
]}

Joshi, Amit ^{[1
]}

Ramaswamy, Anant ^{[1
]}

Dhumal, Sachin ^{[1
]}

Juvekar, Shashikant ^{[2
]}

Arya, Supreeta ^{[2
]}

Mahajan, Abhishek ^{[2
]}

Chaturvedi, Pankaj ^{[3
]}

D'Cruz, Anil ^{[3
]}

Bhattacharjee, Atanu ^{[4
,5
]}

Prabhash, Kumar ^{[1
]}

机构：

[1] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India

[2] Tata Mem Hosp, Dept Radiodiag, Bombay, Maharashtra, India

[3] Tata Mem Hosp, Dept Surg Oncol, Bombay, Maharashtra, India

[4] Tata Mem Hosp, Div Clin Res & Biostat, Bombay, Maharashtra, India

[5] Malabar Canc Ctr, Kannur, Kerala, India

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2017年 / 39卷 / 05期

关键词：

elderly; geriatric; neoadjuvant chemotherapy; induction; head and neck cancers; SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ORAL-CAVITY CANCERS; INDUCTION CHEMOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; UNRESECTABLE HEAD; WEEKLY PACLITAXEL; RANDOMIZED-TRIAL; CISPLATIN; DOCETAXEL;

D O I：

10.1002/hed.24694

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundThe purpose of this study was to present our findings on the treatment completion rates and outcomes in geriatric patients with head and neck cancer treated with neoadjuvant chemotherapy followed by definitive therapy. MethodsGeriatric patients with locally advanced head and neck cancer who received neoadjuvant chemotherapy were selected for this analysis. Overall survival (OS) and progression-free survival (PFS) were estimated. ResultsForty-six of 49 patients completed neoadjuvant chemotherapy (93.9%). The compliance to local treatment was 73.3% and the median OS was 49.9 months (95% confidence interval [CI] = 22.0-77.8 months) in patients who received neoadjuvant chemotherapy for organ preservation (n = 15). In patients receiving neoadjuvant chemotherapy for technically unresectable disease, the corresponding figures were 82.06% and 9.0 months (95% CI = 5.9-12.1 months), respectively. ConclusionIndividualized neoadjuvant chemotherapy protocols in geriatric patients have high compliance rates to treatment and the median OS in geriatric patients treated for organ preservation is similar to that of young patients. (c) 2017 Wiley Periodicals, Inc. Head Neck 39: 886-892, 2017

引用

页码：886 / 892

页数：7

共 50 条

[1] Neoadjuvant chemotherapy in technically unresectable head and neck cancers: a retrospective audit
Mishra, Bal Krishna
Kapoor, Akhil
Gupta, Anuj
Sansar, Bipinesh
Singh, Arpita
Roy, Somnath
Mandal, Tanmoy
Srinivas, Sujay
Das, Sudeep
Mishra, Aseem
Mukherjee, Ashutosh
Nanda, Sambit
Sambasivaiah, Kurupathy
[J]. ECANCERMEDICALSCIENCE, 2022, 16
[2] Development of hyponatremia on neoadjuvant chemotherapy in locally advanced head & neck cancers
Poladia, B.
Patil, V.
Noronha, V.
Joshi, A.
Sharma, V.
Punatar, S.
Sahu, A.
Goyal, G.
Dhumal, S.
Prabhash, K.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S768 - S768
[3] Incidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers
Turkar, S. W.
Chougule, A.
Patil, V.
Noronha, V.
Joshi, A.
Pande, N.
Chandrashekharan, A.
Prabhash, K.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[4] DPD mutation in neoadjuvant chemotherapy in head and neck cancers. Myth or reality?
Patil, V.
Noronha, V.
Joshi, A.
Zanwar, S.
Ramaswamy, A.
Arya, S.
Mahajan, A.
Bhattacharjee, A.
Prabhash, K.
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : S31 - S31
[5] Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center
Patil, V. M.
Noronha, V
Joshi, A.
Krishna, V. M.
Dhumal, S.
Chaudhary, V
Juvekar, S.
Pai, P. S.
Pankaj, C.
Chaukar, D.
Dcruz, A. K.
Prabhash, K.
[J]. INDIAN JOURNAL OF CANCER, 2014, 51 (02) : 100 - 103
[6] Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
Patil, Vijay M.
Noronha, Vanita
Joshi, Amit
Zanwar, Saurabh
Ramaswamy, Anant
Arya, Supreeta
Mahajan, Abhishek
Bhattacharjee, Atanu
Prabhash, Kumar
[J]. SOUTH ASIAN JOURNAL OF CANCER, 2016, 5 (04) : 182 - 185
[7] Neoadjuvant metronomic chemotherapy in locally advanced head and neck cancers - feasibility study
Sultania, M.
Deo, S. V. S.
Shukla, N. K.
Sharma, A.
Sahu, R. K.
Bhasker, S.
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S106 - S106
[8] ADJUVANT AND NEOADJUVANT TREATMENT OF HEAD AND NECK CANCERS
JACOBS, C
[J]. SEMINARS IN ONCOLOGY, 1991, 18 (06) : 504 - 514
[9] REGIONAL CHEMOTHERAPY IN THE HEAD AND NECK CANCERS
SPERANZA, GB
SARTORI, S
MEGALE, C
GIGLIO, A
CAMILLUZZI, E
LENTINI, D
ALBERTI, AM
FOGGI, CM
[J]. MEDICINA-RIVISTA DELLA ENCICLOPEDIA MEDICA ITALIANA, 1985, 5 (03): : 333 - 335
[10] Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers
Chougule, Anuradha
Patil, Vijay M.
Noronha, Vanita
Joshi, Amit
Turkkar, Siddharth
Chandrasekharan, Arun
Pande, Nikhil
Bagayatkar, Priyanka
Prabhash, Kumar
[J]. ORAL ONCOLOGY, 2017, 70 : 73 - 74

← 1 2 3 4 5 →